ArticleGene therapy1999
An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer.
Article in Gene therapy, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 86 citations in OpenAlex.
- Engineered Feedback Employing Natural Hypoxia-Responsive Factors Enhances Synthetic Hypoxia Biosensors.ACS synthetic biology · 2025Article
- Cell-specific gene therapy driven by an optimized hypoxia-regulated vector reduces choroidal neovascularization.Journal of molecular medicine (Berlin, Germany) · 2018Article
- Characterization of neural stem cells modified with hypoxia/neuron-specific VEGF expression system for spinal cord injury.Gene therapy · 2018Article
- The eIF4E2-Directed Hypoxic Cap-Dependent Translation Machinery Reveals Novel Therapeutic Potential for Cancer Treatment.Oxidative medicine and cellular longevity · 2017Review
- A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization.Investigative ophthalmology & visual science · 2014Article
- Hypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapy.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- A novel hybrid promoter responsive to pathophysiological and pharmacological regulation.Journal of molecular medicine (Berlin, Germany) · 2012Article
- Strategies To Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy.Cancers · 2011Article
- Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours.Gene therapy · 2010Article
- Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.Journal of neuro-oncology · 2009Review
- Hypoxia-induced human endonuclease G expression suppresses tumor growth in a xenograft model.Cancer gene therapy · 2008Article
- Robust hypoxia-selective regulation of a retinal pigment epithelium-specific adeno-associated virus vector.Molecular vision · 2008Article
- A novel chimeric promoter that is highly responsive to hypoxia and metals.Gene therapy · 2006Article
- Enhanced efficacy of radiation-induced gene therapy in mice bearing lung adenocarcinoma xenografts using hypoxia responsive elements.Cancer science · 2005Article
- Employing tumor hypoxia for oncolytic therapy in breast cancer.Journal of mammary gland biology and neoplasia · 2005Review
- A novel adenoviral vector which mediates hypoxia-inducible gene expression selectively in neurons.Gene therapy · 2005Article
- A hypoxia-inducible vigilant vector system for activating therapeutic genes in ischemia.Gene therapy · 2005Article
- Effect of hypoxia on Ad5 infection, transgene expression and replication.Gene therapy · 2005Article
- Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization.Gene therapy · 2003Article
- Defining the success of cardiac gene therapy: how can nuclear imaging contribute?European journal of nuclear medicine and molecular imaging · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant adenoviral vectors have a number of advantages for gene therapy, including transduction of a range of dividing and non-dividing cell types. However, this broad range may be a disadvantage if non-target cells are transduced and are adversely affected by expression of the transferred gene. Here we describe a novel adenoviral vector in which transcription of the transgene is restricted to the patho-physiological condition of low oxygen tension (hypoxia). Hypoxia activates the expression of a number of genes, principally via the stabilisation of members of the bHLH/PAS family of transcription factors that bind to a con- sensus DNA sequence, the hypoxia response element (HRE). We have configured an optimised HRE expression cassette into an adenoviral vector, AdOBHRE. A range of cell types, including primary human skeletal muscle, when transduced with AdOBHRE display a low basal level of transgene expression that is highly induced in hypoxia to levels equivalent to that obtained from the CMV promoter. The AdOBHRE vector could be exploited for transcriptionally targeted gene therapy for the treatment of diseases such as cancer, peripheral arterial disease, arthritis and anaemia where tissue hypoxia is a cardinal feature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.